Quick Dispatch:
Your tirzepatide cvot trial Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cvot trial Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism ships.
Need Help?
Questions about tirzepatide cvot trial Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cvot trial Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism in your area.
01324-6/asset/4a54a807-9d4c-43b0-9cee-525570c8c25d/main.assets/gr2_lrg.jpg)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
25.05
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
28.72
Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide
21.48
SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I
29.79
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
29.71
Frontiers
22.71
AHA 25: SURPASS-CVOT: Tirzepatide vs Dulaglutide for Heart Failure in T2D
20.83
